TriNetX-Regeneron $200 Mn Life Sciences Collaboration

Collaboration boosts Regeneron's EHR database via exclusive ~300M patient data access. Genomic/proteomic integration accelerates R&D, drug discovery, AI solutions with $200M TriNetX investment.

Cambridge, Massachusetts-based TriNetX, a leading global health research network, and Regeneron Pharmaceuticals, a biotechnology pioneer in genetics-driven medicines, have recently announced their strategic collaboration.

The agreement provides Regeneron with exclusive access to de-identified electronic health records (EHRs) from approximately 300 million patients across TriNetX's worldwide network of health systems.

This encompasses longitudinal data from 170 million individuals in the United States, plus millions more internationally, with Regeneron able to securely license both existing and prospectively generated anonymized records.

At the core of the partnership, Regeneron's vast genomic and proteomic datasets, drawn from the Regeneron Genetics Center (RGC), which has sequenced over 2 million exomes and genomes, integrate with TriNetX's rich phenotypic data platform.

Advanced privacy-preserving methods, such as federated querying and secure data matching, allow subsets of TriNetX's anonymized EHRs to link directly with RGC records. The result is a massively scaled EHR-linked database that merges multi-omic (genomic, proteomic) insights with real-world clinical phenotypes, directly supporting Regeneron's drug discovery and development pipeline.

This expanded resource accelerates multiple areas, including identifying novel therapeutic targets through population-scale analysis, streamlining clinical trial design with real-world evidence, and enabling digital health innovations for consumers, patients, and providers.

It also facilitates research into AI-driven algorithms for predictive modeling and precision medicine, analyzing health trends at unprecedented scale while adhering to global privacy standards like HIPAA and GDPR via de-identification protocols.

Regeneron commits up to $200 million in investment to TriNetX as part of the deal. “We are delighted to work with Regeneron, and specifically the Regeneron Genetics Center team, to advance human health through the application of intelligence-driven information technology, powered by our trusted data,” said Jeff Margolis, TriNetX executive chairman. “Our team is gratified to be selected by Regeneron to provide access to TriNetX’s unique breadth and depth of research-ready data, across our extensive federated global network of academic medical centres and other leading healthcare research sites.”

TriNetX continues to serve other life sciences organizations through its open platform, while Regeneron secures exclusive rights to these unique data linkages.

The network's coverage spans thousands of health systems globally, delivering detailed, longitudinal patient journeys that enhance Regeneron's competitive edge in the real-world data landscape.

Stay tuned for more such updates on Digital Health News